B+
Bull case
20%
Probability
Target price
$8.00
+70.9% vs current
ENLV
EnlivexBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$5.00
+6.8% vs current
B-
Bear case
30%
Probability
Target price
$2.50
-46.6% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+49.5
Score
AI commentary
The latest company headline is directionally positive because of the RMAT designation, but the evidence base remains thin. The packet provides no social coverage, verified post-release price reaction, analyst revisions, or options/short-interest data; confidence therefore remains capped and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-07-17
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-13eventFDA grants RMAT designation for AllocetraHigh impact
The FDA granted RMAT designation for Allocetra in age-related knee osteoarthritis, enabling intensive FDA engagement and potential expedited-development pathways. A Type B meeting was requested, but its date is not yet disclosed. [#PR-2026-07-13]
2026-11-09catalystNasdaq bid-price compliance overhangHigh impact
The company previously disclosed a Nasdaq minimum-bid-price notice with a compliance deadline of November 9, 2026, creating potential reverse-split or delisting-process risk if compliance is not regained. [#PR-2026-05-15]
2027-06-30catalystPhase 2b knee-OA trial execution and topline dataHigh impact
Enlivex is conducting a randomized Phase 2b trial planned to enroll 182 patients and stated that topline data may be available by the end of Q2 2027. [#PR-2026-07-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology